electroCore, Inc. (NASDAQ:ECOR – Free Report) – Research analysts at HC Wainwright boosted their FY2026 EPS estimates for electroCore in a note issued to investors on Thursday, November 5th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($1.06) for the year, up from their previous forecast of ($1.34). The consensus estimate for electroCore’s current full-year earnings is ($1.17) per share. HC Wainwright also issued estimates for electroCore’s Q4 2026 earnings at ($0.05) EPS, Q1 2027 earnings at ($0.05) EPS, Q2 2027 earnings at ($0.04) EPS, Q3 2027 earnings at ($0.04) EPS, Q4 2027 earnings at $0.05 EPS and FY2027 earnings at ($0.06) EPS.
Separately, Weiss Ratings restated a “sell (d-)” rating on shares of electroCore in a research note on Monday, September 21st. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, electroCore presently has a consensus rating of “Hold” and an average price target of $18.00.
Read Our Latest Stock Report on ECOR
electroCore Stock Performance
NASDAQ ECOR opened at $7.72 on Monday. The firm has a market capitalization of $71.26 million, a P/E ratio of -5.55 and a beta of 1.23. The stock has a 50-day simple moving average of $9.19 and a two-hundred day simple moving average of $7.76. electroCore has a fifty-two week low of $4.41 and a fifty-two week high of $12.70.
electroCore (NASDAQ:ECOR – Get Free Report) last posted its quarterly earnings results on Wednesday, November 4th. The company reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.27) by $0.14. The business had revenue of $9.69 million during the quarter, compared to analysts’ expectations of $10.93 million.
Hedge Funds Weigh In On electroCore
A hedge fund recently bought a new stake in electroCore stock. WealthShield Partners LLC bought a new stake in electroCore, Inc. (NASDAQ:ECOR – Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm bought 25,978 shares of the company’s stock, valued at approximately $157,000. WealthShield Partners LLC owned approximately 0.32% of electroCore at the end of the most recent reporting period. 26.74% of the stock is currently owned by institutional investors and hedge funds.
Insider Transactions at electroCore
In related news, Director Thomas Errico purchased 5,000 shares of the firm’s stock in a transaction that occurred on Monday, September 14th. The shares were purchased at an average cost of $9.82 per share, with a total value of $49,100.00. Following the purchase, the director owned 363,904 shares of the company’s stock, valued at $3,573,537.28. This represents a 1.39% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Joshua S. Lev sold 3,000 shares of electroCore stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $9.36, for a total value of $28,080.00. Following the completion of the sale, the chief financial officer owned 84,889 shares in the company, valued at approximately $794,561.04. The trade was a 3.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 20,000 shares of company stock valued at $200,120 in the last three months. Corporate insiders own 7.80% of the company’s stock.
About electroCore
electroCore, Inc. (NASDAQ: ECOR) is a commercial-stage medical device company focused on bioelectronic medicine and non-invasive vagus nerve stimulation (nVNS). Its technology is designed to stimulate the vagus nerve through the neck without requiring surgery or implanted components. The company’s primary prescription product is gammaCore, a handheld nVNS device used for the acute treatment of pain associated with migraine and episodic cluster headaches in adults. electroCore also markets consumer-oriented products, including Truvaga, a handheld vagus nerve stimulation device positioned for general wellness applications.
Featured Articles
- Five stocks we like better than electroCore
- Why Kinder Morgan’s Chairman Just Bought $15 Million in Stock
- Rocket Lab’s Record Backlog Could Fuel a Rebound, But Neutron Raises the Stakes
- Don’t Let Their Low Yields Fool You: 3 Dividend Stocks Worth Watching
- A $4 Billion Jolt: NRG Energy Powers Data Center Ambitions
Receive News & Ratings for electroCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for electroCore and related companies with MarketBeat.com's FREE daily email newsletter.
